Our proprietary ultra-low Radio Frequency Energy (ulRFE™) technology produces a cognate of solvated molecules by measuring and recording their electrostatic surface potential as an oscillating magnetic field. The ulRFE cognate is delivered locally and non-systemically via a medical device. Pre-clinical and clinical studies suggest the ability to specifically regulate metabolic pathways and/or replicate known mechanisms of action for proven commercial drugs. To date, no adverse effects or toxicity related to the device have been observed in human clinical trials.
Note: Nativis Voyager® ulRFE™ System for rGBM is an investigational medical device. Limited by Federal (or United States) law to investigational use only.
Every molecule has a unique electrostatic potential. The electrostatic potential is critically important to the chemical properties of a molecule and how a molecule interacts with, and in, a biological system. Our ‘Super Conducting Quantum Interference Device’ (SQUID) based technology measures the unique electrostatic potential of a molecule, as specific Radio Frequency Energy (RFE). This unique and specific RFE is used to induce electron and charge transfer in a defined bioactive target, altering cell dynamics to produce a therapeutic response.